Usual Adult Dose for Postoperative Ocular Inflammation

0.1% suspension: 1 drop applied to the affected eye 3 times a day beginning 1 day before cataract surgery, continued the day of surgery and through the first 2 weeks of the postoperative period

0.3% suspension: 1 drop applied to the affected eye once a day beginning 1 day before cataract surgery, continued the day of surgery and through the first 2 weeks of the postoperative period; an additional drop should be administered 30 to 120 minutes before surgery

Comments:

• This drug may be administered in conjunction with other topical ophthalmic drugs such as beta-blockers, carbonic anhydrase inhibitors, alpha-agonists, cycloplegics, and mydriatics.
• If more than one topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.

Usual Pediatric Dose for Postoperative Ocular Inflammation

10 years or older:
0.1% suspension: 1 drop applied to the affected eye 3 times a day beginning 1 day before cataract surgery, continued the day of surgery and through the first 2 weeks of the postoperative period

0.3% suspension: 1 drop applied to the affected eye once a day beginning 1 day before cataract surgery, continued the day of surgery and through the first 2 weeks of the postoperative period; an additional drop should be administered 30 to 120 minutes before surgery

Comments:

• This drug may be administered in conjunction with other topical ophthalmic drugs such as beta-blockers, carbonic anhydrase inhibitors, alpha-agonists, cycloplegics, and mydriatics.
• If more than one topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:

• Hypersensitivity to the active component, other NSAIDs, or any of the ingredients

Dialysis

Data not available

Other Comments

Administration advice:

• The bottle should be shaken well prior to administration.
• This drug is for ophthalmic use only; it should not be swallowed or injected.
• Nasolacrimal occlusion and instructing the patient to gently close the eyelid following instillation may reduce systemic absorption of this drug.
• Care should be taken not to touch the eyelids, surrounding areas or other surfaces with the dropper tip of the bottle.

• Protect from light and store below 25C.
• Bottle should be kept tightly closed when not in use.

• Patients should be advised not to swallow this drug.
• Patients should be told to avoid sunlight during treatment.
• Patients should be instructed to shake the bottle well before use.
• This drug may cause temporary changes in vision; patients should avoid driving or operating machinery until their vision clears.